Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Ruby Khatun Khatun
    Ruby Khatun Khatun
      • Home
      • Ruby Khatun Khatun

      Articles By : Ruby Khatun Khatun

      Actelion antibiotic misses mark on one study, hits it on another

      Actelion antibiotic misses mark on one study, hits it on another

      Ruby Khatun Khatun10 Jun 2017 10:54 AM IST
      Swiss biotechnology company Actelion on Thursday presented mixed trial results for its antibiotic hopeful cadazolid, saying it met the main goal of...
      Hester Biosciences board approves 3 million dollar investment in African arm

      Hester Biosciences board approves 3 million dollar investment in African arm

      Ruby Khatun Khatun9 Jun 2017 11:54 AM IST
      New Delhi: Hester Biosciences said its board has approved investing USD 3 million (over Rs 19 crore) in the companys wholly-owned subsidiary, Hester...
      Is the Sun Sinking- Dilip Shanghvi loses 14 Billion Dollars in 2 Years

      Is the Sun Sinking- Dilip Shanghvi loses 14 Billion Dollars in 2 Years

      Ruby Khatun Khatun9 Jun 2017 11:29 AM IST
      Bloomberg Report; By Ari AltstedterDilip Shanghvi’s shrinking fortune has become one of the most visible casualties of the troubles hitting India’s...
      Vivimed Labs soars on Nil observation from USFDA

      Vivimed Labs soars on Nil observation from USFDA

      Ruby Khatun Khatun9 Jun 2017 11:29 AM IST
      Vivimed Labs gained as USFDA has given zero 483 observations after inspecting the company's API manufacturing facility in Sant Celoni, Spain.The...
      Novartis touts new T-cell therapy data in race for FDA approval

      Novartis touts new T-cell therapy data in race for FDA approval

      Ruby Khatun Khatun9 Jun 2017 11:29 AM IST
      ZURICH: Novartis on Wednesday touted new data from its T-cell therapy CTL019, saying it is on a par with results of experimental molecules from Kite...
      Gufic Biosciences gets two patent certificates; stock soars over 5%

      Gufic Biosciences gets two patent certificates; stock soars over 5%

      Ruby Khatun Khatun9 Jun 2017 11:29 AM IST
      Mumbai: Gufic Biosciences on Monday informed the bourses that it has received two patent certificates from the Intellectual Property India, The Patent...
      Unichem lines up Rs 350 crore capex for next two years

      Unichem lines up Rs 350 crore capex for next two years

      Ruby Khatun Khatun9 Jun 2017 11:28 AM IST
      New Delhi: Drug firm Unichem Laboratories has lined up a capex of around Rs 350 crore for the next two years as it plans to strengthen R&D...
      Strides Shasun Gets USFDA Approval For Parkinsons Drug

      Strides Shasun Gets USFDA Approval For Parkinsons Drug

      Ruby Khatun Khatun9 Jun 2017 11:28 AM IST
      New Delhi: Strides Shasun said it has received approval from the US health regulator for Amantadine Hydrochloride, used for the treatment of...
      South Korea to fine Novartis unit over unfair drug promotions

      South Korea to fine Novartis unit over unfair drug promotions

      Ruby Khatun Khatun9 Jun 2017 10:24 AM IST
      South Korea's antitrust regulator said it would fine Novartis' local unit 500 million won ($444,089) for alleged unfair promotions, in another setback...
      Cadila Healthcare beats Lupin to become 2nd most valued pharma company in India

      Cadila Healthcare beats Lupin to become 2nd most valued pharma company in India

      Ruby Khatun Khatun8 Jun 2017 2:26 PM IST
      New Delhi: Shares of Cadila Healthcare surged nearly 10 per cent, helping the company overtake Lupin to become the second most valued pharma firm in...
      Zydus Cadila gets USFDA nod for mesalamine tablets

      Zydus Cadila gets USFDA nod for mesalamine tablets

      Ruby Khatun Khatun8 Jun 2017 2:24 PM IST
      New Delhi: Drug firm Zydus Cadila said it has received the US health regulator's nod to market mesalamine tablets, used for the treatment of...
      Tevas migraine drug clears another hurdle, aims for launch in 2018

      Teva's migraine drug clears another hurdle, aims for launch in 2018

      Ruby Khatun Khatun8 Jun 2017 1:27 PM IST
      Teva Pharmaceutical Industries Ltd said on Wednesday its experimental drug to prevent migraines cleared another late-stage study, setting it on course...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok